grant
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
Organization STATE UNIVERSITY OF NEW YORK AT BUFFALOLocation AMHERST, UNITED STATESPosted 15 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025(TNF)-αAdverse effectsAnxietyAreaB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BiologicalBlood Cell CountBlood Cell NumberCSF3CSF3 geneCachectinCancer PatientCancer ScienceCancer TreatmentCancersCannabisCellular Immune FunctionCheckpoint inhibitorClinicalClinical DataCo-StimulatorCognitiveCollaborationsComputerized Medical RecordConsumptionCostimulatorCross Sectional AnalysisCross-Sectional AnalysesCross-Sectional StudiesCross-Sectional SurveyD.C. WashingtonDC WashingtonDataDecrease disparityDiseaseDisease Frequency SurveysDisease ProgressionDisorderDisparitiesDisparityDistrict of ColumbiaDizzinessEcological momentary assessmentElectronic Medical RecordEpidermal Thymocyte Activating FactorExhibitsFatigueFundingG-CSFGCSFGM-CSFGoalsGranulocyte-Macrophage Colony-Stimulating FactorHPGFHepatocyte-Stimulating FactorHistamine-Producing Cell-Stimulating FactorHybridoma Growth FactorIFN-beta 2IFNB2IL-2IL-6IL2 ProteinIL6 ProteinImmune MarkersImmune checkpoint inhibitorImmune mediated therapyImmune systemImmunologic MarkersImmunologically Directed TherapyImmunologyImmunomodulationImmunooncologyImmunotherapyIndividualInterdisciplinary ResearchInterdisciplinary StudyInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-2Interleukin-6Interleukine 2Interleukine 2 PrecursorInterleukine IIKnowledgeLack of EnergyLegalLinkLongitudinal StudiesLower disparityLymphocyte Mitogenic FactorMGC45931MGI-2Macrophage-Derived TNFMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMeasuresMedical MarijuanaMedicinal MarijuanaMemory DeficitMemory impairmentMental HealthMental HygieneMethodsMitogenic FactorMolgramostinMonocyte-Derived TNFMoodsMultidisciplinary CollaborationMultidisciplinary ResearchMyeloid Differentiation-Inducing ProteinNCI-Designated Cancer CenterOncologistOncologyOncology CancerOutcomePainPainfulPatient CarePatient Care DeliveryPatient Outcomes AssessmentsPatient Reported MeasuresPatient Reported OutcomesPatientsPerformancePersonsPhonePlasmacytoma Growth FactorPrevalenceProspective, cohort studyPsychological HealthQOLQualifyingQuality of lifeRenal functionReportingResearchRoleSamplingScheduleScienceSeveritiesSiteSleepSleep disturbancesSolidSurvey InstrumentSurveysSymptomsT cell growth factorT-Cell Growth FactorT-Cell Stimulating FactorTC-GM-CSFTHC co-useTHC useTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTelephoneTestingTetrahydrocannabinol co-useTetrahydrocannabinol useTherapeuticTherapeutic UsesThymocyte Stimulating FactorTimeTumor Necrosis FactorTumor Necrosis Factor-alphaTumor-Cell Human GM Colony-Stimulating Factoraberrant sleepanti-cancer immunotherapyanti-cancer therapyanticancer immunotherapybiologiccancer immunotherapycancer progressioncancer therapycancer-directed therapycannabis usecannabis use disordercannabis usercare for patientscare of patientscaring for patientscheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapycognitive taskcommunity level disadvantagedeprivationdisadvantaged communitydisparity reductiondisrupted sleepdisturbed sleepelectronic dataevidence basehealth equityimmune check point inhibitorimmune check point therapyimmune checkpoint therapyimmune functionimmune modulationimmune regulationimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based biomarkersimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmune-oncologyimmuno oncologyimmuno therapyimmunologic reactivity controlimmunological biomarkersimmunological markersimmunology oncologyimmunomodulatoryimmunoregulationimmunoregulatoryimmunotherapy for cancerimmunotherapy of cancerimpaired sleepimprovedimprovement on sleepindexinginterferon beta 2irregular sleepkidney functionliver functionlong-term studylongitudinal outcome studiesmalignancymanage symptommarijuana usemarijuana use and disordermarijuana use disordermarijuana usermedical cannabismedicinal cannabismemory dysfunctionmitigate disparitymultidisciplinaryneighborhood barrierneighborhood disadvantageneighborhood-level barrierneighborhood-level disadvantageneoplasm progressionneoplasm/cancerneoplastic progressiononcoimmunologypatient safetypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypesprogramsprogression biomarkerprogression markerprospectivereduce disparityreduction in disparityresponsesecondary outcomeside effectsleep disruptionsleep dysregulationsleep improvementsleep/wake disruptionsleep/wake disturbancesocial health determinantssocial rolesubstance misusesymptom managementtherapeutic cannabistherapeutic marijuanatumortumor progressionvirtual
Description preview
Project Abstract
Up to 40% of patients report using cannabis for symptom management during and after cancer treatments
despite gaps in our understanding of its longitudinal therapeutic uses and harms. Simultaneously, immuno-
oncology is a rapidly advancing field of cancer treatment. Nearly 44% of cancer patients across 20 tumor types
receive…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click